Liver transplantation for non-resectable colorectal metastases-an evolving paradigm in transplant oncology  

作　　者：Christian Hobeika Markus Selzner 

机构地区：[1]Ajmera Transplant Centre,Toronto General Hospital,University Health Network,Toronto,ON,Canada [2]Department of HPB Surgery and Liver Transplantation,Beaujon Hospital,APHP,Clichy,Paris-CitéUniversity,Paris,France [3]UMR Inserm 1275 CAP Paris-Tech,Lariboisière Hospital,Paris,Paris-CitéUniversity,Paris,France [4]Department of Surgery,University of Toronto,Toronto,ON,Canada

出　　处：《Hepatobiliary Surgery and Nutrition》2023年第3期424-427,共4页肝胆外科与营养（英文）

摘　　要：A better understanding of colorectal liver metastasis(CRLM)onco-genomics and the improvement of systemic treatments,including targeted and immune therapies,have shifted the paradigm of CRLM prognosis over the past two decades.While 40%of the patients with colorectal cancers are likely to develop CRLM[and 50%of them to be non-resectable(nCRLM)],current oncologic management allows for the identification of a subset of CRLM patients with controlled diseases likely to highly benefit from curative resections and,perhaps,liver transplantation(LT).Indeed,the Norwegian SECA I trial in 2013(1)triggered a growing interest in LT as a curative treatment for non-resectable colorectal liver metastasis(nCRLM).This strategy is supported by several pilot studies reporting up to 80%of 5-year estimated overall survival(OS)after LT for CRLM,in contrast to the poor results obtained in the early 80’s series.

关 键 词：Colorectal cancer liver metastasis transplant oncology guidlines liver transplantation(LT) organ shortage living donor 

分 类 号：R735.7[医药卫生—肿瘤]